BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Melanoma clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for melanoma: 262 (174 sponsors; 18 newly posted in the last 180 days, 14 stopped in the last 180 days; 8 new-entrant sponsors). Momentum score 7.6, rank 84 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 3, Phase 1 75, Phase 2 108, Phase 3 38, Phase 4 2, N/A 36.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Regeneron Pharmaceuticals REGN9P3 4, P2 522
Bristol-Myers Squibb BMY9P2 3, NA 2, P3 3, P4 101
Merck Sharp & Dohme LLC MRK6P2 3, P3 300
IDEAYA Biosciences IDYA5P2 2, P3 313
Biocad4P3 3, P1 101
Replimune, Inc. REPL5P2 1, NA 1, P1 1, P3 200
Philogen S.p.A.3P2 1, P3 200
Immunocore Ltd IMCR2P3 200
Aura Biosciences AURA4P3 1, NA 300
Iovance Biotherapeutics, Inc. IOVA4P2 3, P3 100
Pfizer PFE4P3 1, P1 300
Immatics US, Inc. IMTX3P2 1, P1 1, P3 100
Binhui Biopharmaceutical Co., Ltd.2P2 1, P3 100
Erasca, Inc. ERAS2P3 1, P1 100
IO Biotech2P3 1, P2 100
Linnaeus Therapeutics, Inc.2P3 1, P2 100
Pierre Fabre Medicament2P3 1, P1 101
Scancell Ltd SCNLD2P2 1, P3 111
Amgen AMGN1P3 100
Delcath Systems Inc. DCTH1P3 100
Eikon Therapeutics EIKN1P3 100
HUYABIO International, LLC.1P3 100
mAbxience Research S.L.1P3 101
Shanghai Kechow Pharma, Inc.1P3 100
Novartis Pharmaceuticals NVS6P2 2, P1 2, P4 1, NA 101

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2Shanghai JMT-Bio Inc.NCT07280832 Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsUnresectable Locally Advanced or Metastatic Melanoma; Unresectable Locally Advanced or Metastatic Urrecruiting500
2026-12 est.P1/P2Sapience TherapeuticsNCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsGlioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brainactive not recruiting125
2026-12 est.P1/P2Beijing Scitech-Mq Pharmaceuticals LimitedNCT06359860 A Study of ST-1898 for Unresectable or Metastatic MelanomaUnresectable or Metastatic Melanomaactive not recruiting64
2026-12 est.P1/P2Georgiamune IncNCT06425926 Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsMelanoma Stage IV; Solid Tumorrecruiting117
2026-12-15 est.P1/P2GV20 TherapeuticsNCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesSolid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma;recruiting365
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT06797297 A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic MucosalMelanomaactive not recruiting203
2027-01 est.P3BiocadNCT05751928 A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaMelanoma Stage III; Melanoma (Skin)active not recruiting411
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-01-15 est.P3Regeneron Pharmaceuticals REGNNCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it HasMelanomaactive not recruiting1564
2027-01-15 est.P2/P3IDEAYA Biosciences IDYANCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaMetastatic Uveal Melanomaactive not recruiting420
2027-01-29 est.P1/P2IDEAYA Biosciences IDYANCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsMetastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumorsrecruiting336
2027-01-31 est.P2Scancell Ltd SCNLDNCT04079166 SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)Malignant Melanoma; Melanoma (Skin); Melanoma Stage III; Melanoma Stage IVactive not recruiting173
2027-02-02 est.P2Novartis Pharmaceuticals NVSNCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaMelanomaactive not recruiting134

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2026-07-30FDA AdComheldReplimune, Inc. REPLAdCom 2026-07-30: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125827

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-02 est.P2Regeneron Pharmaceuticals REGNNCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaMelanomaactive not recruiting151
2026-10-30 est.P3Pfizer PFENCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaMelanomaactive not recruiting257
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-13 est.P1/P2GlaxoSmithKlineNCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerMelanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinactive not recruiting83
2026-10 est.P2Vyriad, Inc.NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsMelanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Canceractive not recruiting87
2026-09-30 est.P1/P2Shanghai Pharmaceuticals Holding Co., LtdNCT06214156 A Clinical Study of T3011 in Subjects With Advanced MelanomaAdvanced Melanomarecruiting42
2026-09-22 est.P1/P2ImmVira Pharma Co. LtdNCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or MeSolid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLCrecruiting30
2026-09-09P1/P2BioInvent International ABNCT06784648 Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaMelanoma Metastatic; Melanoma of Skin; Melanoma BRAF V600E/K Mutated; Melanoma Recurrent; Melanoma Sactive not recruiting35
2026-08-01 est.P1/P2OncoResponse, Inc.NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsCancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanomrecruiting168
2026-07 est.P1/P2CJ Bioscience, Inc.NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerNSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancerrecruiting160
2026-07 est.P3HUYABIO International, LLC.NCT04674683 Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaUnresectable or Metastatic Melanoma; Progressive Brain Metastasisactive not recruiting450
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06-02P1/P2Binhui Biopharmaceutical Co., Ltd.NCT04386967 OH2 Injection in Solid TumorsSolid Tumor; Melanomacompleted44
2026-06 est.P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06500091 TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid TumorsSoft Tissue Sarcoma; Melanomanot yet recruiting54

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "melanoma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.